| MeSH term | MeSH ID | Detail |
|---|---|---|
| Immune Reconstitution Inflammatory Syndrome | D054019 | 1 associated lipids |
| Serositis | D012700 | 1 associated lipids |
| Euthyroid Sick Syndromes | D005067 | 1 associated lipids |
| Glossitis, Benign Migratory | D005929 | 1 associated lipids |
| Parotid Diseases | D010305 | 1 associated lipids |
| Extensively Drug-Resistant Tuberculosis | D054908 | 1 associated lipids |
| Sacroiliitis | D058566 | 1 associated lipids |
| Achlorhydria | D000126 | 1 associated lipids |
| Upper Extremity Deep Vein Thrombosis | D056824 | 1 associated lipids |
| Pseudomyxoma Peritonei | D011553 | 1 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Mosdósi B et al. | Severe acrocyanosis precipitated by cold agglutinin secondary to infection with Mycoplasma pneumoniae in a pediatric patient. | 2017 | Croat. Med. J. | pmid:29308834 |
| Zhang X and Hu C | Selecting optimal columns for clarithromycin impurity analysis according to the quantitative relationship of hydrophobic subtraction model. | 2017 | J Pharm Biomed Anal | pmid:28024686 |
| Addo KK et al. | Genotyping and drug susceptibility testing of mycobacterial isolates from population-based tuberculosis prevalence survey in Ghana. | 2017 | BMC Infect. Dis. | pmid:29197331 |
| Baluch A et al. | Successful management of Mycobacterium haemophilum lower extremity cutaneous infection in a matched-unrelated donor stem cell transplant recipient. | 2017 | Transpl Infect Dis | pmid:27775824 |
| Maruyama M et al. | Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Eradication: A Randomized Controlled Trial. | 2017 | Can J Gastroenterol Hepatol | pmid:28349044 |
| Brouqui P et al. | Old antibiotics for emerging multidrug-resistant/extensively drug-resistant tuberculosis (MDR/XDR-TB). | 2017 | Int. J. Antimicrob. Agents | pmid:28336312 |
| Xu YF et al. | and Antibacterial Activities of Patchouli Alcohol, a Naturally Occurring Tricyclic Sesquiterpene, against Helicobacter pylori Infection. | 2017 | Antimicrob. Agents Chemother. | pmid:28320722 |
| Yang YJ et al. | Ten days of levofloxacin-containing concomitant therapy can achieve effective Helicobacter pylori eradication in patients with type 2 diabetes. | 2017 | Ann. Med. | pmid:28266875 |
| Geng X et al. | The Bifunctional Enzyme SpoT Is Involved in the Clarithromycin Tolerance of Helicobacter pylori by Upregulating the Transporters HP0939, HP1017, HP0497, and HP0471. | 2017 | Antimicrob. Agents Chemother. | pmid:28242673 |
| Larsen EL et al. | Clarithromycin, trimethoprim, and penicillin and oxidative nucleic acid modifications in humans: randomised, controlled trials. | 2017 | Br J Clin Pharmacol | pmid:28185274 |
| Park SM et al. | Randomized clinical trial comparing 10- or 14-day sequential therapy and 10- or 14-day concomitant therapy for the first line empirical treatment of Helicobacter pylori infection. | 2017 | J. Gastroenterol. Hepatol. | pmid:27505301 |
| Yoon HY et al. | Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease. | 2017 | Int. J. Tuberc. Lung Dis. | pmid:28826448 |
| Yoon H et al. | Eradication Downregulates Cellular Inhibitor of Apoptosis Protein 2 in Gastric Carcinogenesis. | 2017 | Gut Liver | pmid:27282269 |
| Nanishi E et al. | Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control Study. | 2017 | J Am Heart Assoc | pmid:28684643 |
| Boal Carvalho P et al. | Randomized Controlled Trial for Helicobacter pylori Eradication in a Naive Portuguese Population: Is Sequential Treatment Superior to Triple Therapy in Real World Clinical Setting? | 2017 | Acta Med Port | pmid:28550827 |
| Shah SA et al. | Clarithromycin inhibits TNF-α-induced MUC5AC mucin gene expression via the MKP-1-p38MAPK-dependent pathway. | 2017 | Int. Immunopharmacol. | pmid:28550735 |
| Osaki T et al. | Usefulness of detection of clarithromycin-resistant Helicobacter pylori from fecal specimens for young adults treated with eradication therapy. | 2017 | Helicobacter | pmid:28544222 |
| Chang CT et al. | Antibiotic treatment of zebrafish mycobacteriosis: tolerance and efficacy of treatments with tigecycline and clarithromycin. | 2017 | J. Fish Dis. | pmid:28422304 |
| Jakubů V et al. | Trends in the Minimum Inhibitory Concentrations of Erythromycin, Clarithromycin, Azithromycin, Ciprofloxacin, and Trimethoprim/Sulfamethoxazole for Strains of Bordetella pertussis isolated in the Czech Republic in 1967-2015. | 2017 | Cent. Eur. J. Public Health | pmid:29346850 |
| Vaz AM et al. | Capsule endoscopy in the diagnosis of disseminated complex infection. | 2017 | BMJ Case Rep | pmid:29167222 |
| Lee H et al. | Concomitant, sequential, and 7-day triple therapy in first-line treatment of Helicobacter pylori infection in Korea: study protocol for a randomized controlled trial. | 2017 | Trials | pmid:29149904 |
| Andere NMRB et al. | Clarithromycin as an Adjunct to One-Stage Full-Mouth Ultrasonic Periodontal Debridement in Generalized Aggressive Periodontitis: A Randomized Controlled Clinical Trial. | 2017 | J. Periodontol. | pmid:28671507 |
| Sotto RB et al. | Sub-lethal pharmaceutical hazard tracking in adult zebrafish using untargeted LC-MS environmental metabolomics. | 2017 | J. Hazard. Mater. | pmid:28623724 |
| Liatsos C and Leontiadis GII | The "report card" to grade H. Pylori treatment regimens: is it achievable in real-world in areas with high clarithromycin resistance? | 2017 | J Gastrointestin Liver Dis | pmid:28617893 |
| Adachi T et al. | Comparative Study of Clarithromycin- versus Metronidazole-Based Triple Therapy as First-Line Eradication for Helicobacter pylori. | 2017 | Oncology | pmid:29258111 |
| Moon SH et al. | Novel Linear Lipopeptide Paenipeptins with Potential for Eradicating Biofilms and Sensitizing Gram-Negative Bacteria to Rifampicin and Clarithromycin. | 2017 | J. Med. Chem. | pmid:29136469 |
| Carneiro MDS et al. | Lack of association between rrl and erm(41) mutations and clarithromycin resistance in Mycobacterium abscessus complex. | 2017 | Mem. Inst. Oswaldo Cruz | pmid:29091138 |
| Feng L et al. | Removal of antibiotics during the anaerobic digestion of pig manure. | 2017 | Sci. Total Environ. | pmid:28628813 |
| Marin AC et al. | Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis. | 2017 | Drugs | pmid:28361211 |
| Holmberg LA et al. | Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin. | 2017 | Acta Haematol. | pmid:28355602 |
| Smith S et al. | The Irish Helicobacter pylori Working Group consensus for the diagnosis and treatment of H. pylori infection in adult patients in Ireland. | 2017 | Eur J Gastroenterol Hepatol | pmid:28350745 |
| Mougari F et al. | Evaluation of the new GenoType NTM-DR kit for the molecular detection of antimicrobial resistance in non-tuberculous mycobacteria. | 2017 | J. Antimicrob. Chemother. | pmid:28333340 |
| Anwar HF et al. | Synthesis of clarithromycin ketolides chemically modified at the unreactive C10-methyl group. | 2017 | Bioorg. Med. Chem. | pmid:28302508 |
| Chey WD et al. | ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. | 2017 | Am. J. Gastroenterol. | pmid:28071659 |
| Fernández Martos R et al. | Acute psychotic episode secondary to Helicobacter pylori eradication treatment. | 2017 | Rev Esp Enferm Dig | pmid:28071063 |
| Takeuchi S et al. | Hypotension induced by the concomitant use of a calcium-channel blocker and clarithromycin. | 2017 | BMJ Case Rep | pmid:28069789 |
| Liou JM et al. | Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection. | 2018 | Gastroenterology | pmid:29964036 |
| Kwofie SK et al. | Screening of Isocitrate Lyase for Novel Anti-Buruli Ulcer Natural Products Originating from Africa. | 2018 | Molecules | pmid:29954088 |
| Tanabe H et al. | Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication. | 2018 | Ann. Clin. Microbiol. Antimicrob. | pmid:29950163 |
| Sandri A et al. | Inhibition of Pseudomonas aeruginosa secreted virulence factors reduces lung inflammation in CF mice. | 2018 | Virulence | pmid:29938577 |
| Gonzalez-Hormazabal P et al. | Prevalence of clarithromycin resistance in Helicobacter pylori in Santiago, Chile, estimated by real-time PCR directly from gastric mucosa. | 2018 | BMC Gastroenterol | pmid:29925321 |
| Fiorini G et al. | Pylera and sequential therapy for first-line Helicobacter pylori eradication: a culture-based study in real clinical practice. | 2018 | Eur J Gastroenterol Hepatol | pmid:29481383 |
| Talarico S et al. | High prevalence of Helicobacter pylori clarithromycin resistance mutations among Seattle patients measured by droplet digital PCR. | 2018 | Helicobacter | pmid:29480566 |
| Takemori N et al. | A novel combination of bortezomib, lenalidomide, and clarithromycin produced stringent complete response in refractory multiple myeloma complicated with diabetes mellitus - clinical significance and possible mechanisms: a case report. | 2018 | J Med Case Rep | pmid:29454372 |
| Xu R et al. | Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban. | 2018 | Eur. J. Clin. Pharmacol. | pmid:29453492 |
| Tsutsui A et al. | Trends and patterns of national antimicrobial consumption in Japan from 2004 to 2016. | 2018 | J. Infect. Chemother. | pmid:29428566 |
| Redondo JJ et al. | A novel RT-PCR for the detection of Helicobacter pylori and identification of clarithromycin resistance mediated by mutations in the 23S rRNA gene. | 2018 | Diagn. Microbiol. Infect. Dis. | pmid:29111147 |
| Iwamoto J et al. | Effects of the Concomitant Use of Low-dose Clarithromycin with an Anti-TNFα Antibody in a Patient with Intestinal Behçet Disease. | 2018 | Intern. Med. | pmid:29093413 |
| Inagaki Y et al. | Disseminated Cutaneous Infection of Mycobacterium colombiense in a Patient with Myelodysplastic Syndrome. | 2018 | Intern. Med. | pmid:29093379 |
| Ullah S et al. | Hydrophilically modified self-assembling α-tocopherol derivative as niosomal nanocarrier for improving clarithromycin oral bioavailability. | 2018 | Artif Cells Nanomed Biotechnol | pmid:28541761 |